Royal Bank of Canada’s Apollomics APLM Stock Holding History

Royal Bank of Canada’s Portfolio APLM Stock Details APLM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-2	Closed	-$1K	–	7077
2023 Q3	$1K	Buy	+2	New	+$978	﹤0.01%	6853

Other funds holding APLM

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

ETC

Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bensler Bellevue, Washington $1.13B AUM 38.91% 1-Year Est. Return

GKFF

George Kaiser Family Foundation Tulsa, Oklahoma $883M AUM 21.04% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

ZIG

Zullo Investment Group Scranton, Pennsylvania $264M AUM 26.77% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Royal Bank of Canada's APLM Position: Q4 2023 in Review

Royal Bank of Canada sold out of Apollomics (APLM) in Q4 2023, closing a stake of 2 shares — an estimated $1K sold.

Royal Bank of Canada first reported a position in APLM in Q3 2023 and held it in 1 quarter. The position peaked at $1K in Q3 2023. 12 funds tracked by Wall St. Rank hold APLM as of Q4 2023.

Royal Bank of Canada reported no remaining Apollomics position as of Q4 2023 after selling out during the quarter.
Royal Bank of Canada sold 2 Apollomics shares in Q4 2023, an estimated $1K.
Royal Bank of Canada first reported a position in Apollomics in Q3 2023 and held it in 1 quarter.
Royal Bank of Canada's Apollomics position peaked at $1K in Q3 2023.
12 funds tracked by Wall St. Rank held Apollomics as of Q4 2023.

Based on Royal Bank of Canada's 13F filing for Q4 2023, filed 14 Feb 2024.